CFB
WGS icon

Cullen/Frost Bankers’s GeneDx Holdings WGS Stock Holding History

Cullen/Frost Bankers’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$566 – 1564
2025
Q4 		$566 Sell
4
-165
-98% -$22.6K ﹤0.01% 1341
2025
Q3 		$18.2K Buy
+169
New +$18.4K ﹤0.01% 963

Other funds holding WGS

CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $722M AUM 97.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cullen/Frost Bankers's WGS Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of GeneDx Holdings (WGS) in Q1 2026, closing a stake of 4 shares — an estimated $566 sold.

Cullen/Frost Bankers first reported a position in WGS in Q3 2025 and held it in 2 quarters. The position peaked at $18.2K in Q3 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Cullen/Frost Bankers reported no remaining GeneDx Holdings position as of Q1 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 4 GeneDx Holdings shares in Q1 2026, an estimated $566.
  • Cullen/Frost Bankers first reported a position in GeneDx Holdings in Q3 2025 and held it in 2 quarters.
  • Cullen/Frost Bankers's GeneDx Holdings position peaked at $18.2K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.